Log In
Print
BCIQ
Print
Print this Print this
 

Anti-HER2-ADC

  Manage Alerts
Collapse Summary General Information
Company Synthon B.V.
DescriptionAntibody-drug conjugate (ADC) consisting of trastuzumab, a humanized mAb against HER2, conjugated to duocarmycin analogs, a class of DNA minor groove-binding agents, using proprietary SpaceLink technology
Molecular Target Epidermal growth factor receptor 2 (EGFR2) (HER2) (ErbB2) (neu)
Mechanism of ActionAntibody-drug conjugate; Epidermal growth factor (EGF) receptor 2 (HER2) (ErbB2) (neu) inhibitor
Therapeutic ModalityBiologic: Antibody-drug conjugate
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today